Development asset linked to Crinetics Pharmaceuticals Europe in public FDA and regional records.
pharma · Congenital Adrenal Hyperplasia · Carcinoid Syndrome · CRNX
Crinetics Pharmaceuticals Europe
Crinetics Pharmaceuticals Europe GmbH
Crinetics Pharmaceuticals Europe drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
6055 Lusk Blvd, San Diego, California 92121, US HQ
2008 Founded
597 Employees
Public company Type
CRNX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 6055 Lusk Blvd, San Diego, California 92121, US
- Founded
- 2008
- Employees
- 597
- Programs
- 12
- Drugs
- 4
- Patents
- 26
Crinetics Pharmaceuticals Europe pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Crinetics Pharmaceuticals Europe drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
paltusotine
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Crinetics Pharmaceuticals Europe's portfolio. Molecular target: Somatostatin receptor type 2.
- Target
- Somatostatin receptor type 2
- Mechanism
- Somatostatin receptor 2 agonist
-
US regulatory status: approved.
-
Development asset linked to Crinetics Pharmaceuticals Europe in public FDA and regional records.